Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akira Hamada

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Pathology International|August 14, 2025
Impact of the IASLC Grading and Other Pathological Features on Relapse and Survival in Completely Resected Lung Adenocarcinoma by EGFR Mutation Status: A Supplementary Analysis of the CReGYT-01 EGFR StudyHironobu Hoshino, Shinya Katsumata, Akira Hamada, et al.
Clinical Lung Cancer|October 27, 2021
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic CarcinomasToshio Fujino, Kenichi Suda, Kazuko Sakai, et al.
Lung Cancer (Amsterdam, Netherlands)|August 30, 2020
Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Keiko Obata, et al.
Kyobu Geka. the Japanese Journal of Thoracic Surgery|September 3, 2016
[Curative Left Pulmonary Resection Combined with Total En Bloc Spondylectomy for Lung Cancer Invading the Second and Third Thoracic Vertebral Bodies]Makoto Endoh, Hiroyuki Oizumi, Hirohisa Kato, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2021
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancerShuta Ohara, Kenichi Suda, Toshio Fujino, et al.
Cancers|December 30, 2025
Refining Surgical Standards: The Role of Robotic-Assisted Segmentectomy in Early-Stage Non-Small-Cell Lung CancerMasaya Nishino, Hideki Ujiie, Masaoki Ito, et al.
Translational Lung Cancer Research|September 29, 2021
Activity and mechanism of acquired resistance to tarloxotinib in <i>HER2</i> mutant lung cancer: an <i>in vitro</i> studyTakamasa Koga, Kenichi Suda, Masaya Nishino, et al.
Clinical Lung Cancer|May 10, 2026
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)Noriko Mitome, Akira Hamada, Masashi Wakabayashi, et al.
Surgery Today|February 21, 2021
The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgeryToshiki Takemoto, Junichi Soh, Shuta Ohara, et al.
Kyobu Geka. the Japanese Journal of Thoracic Surgery|July 2, 2016
[Chest Wall Reconstruction Using Titanium Plates Sandwiched Between Sheets after Resection of Chest Wall Chondrosarcoma]Makoto Endoh, Hiroyuki Oizumi, Hirohisa Kato, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Pathology International|August 14, 2025
Impact of the IASLC Grading and Other Pathological Features on Relapse and Survival in Completely Resected Lung Adenocarcinoma by EGFR Mutation Status: A Supplementary Analysis of the CReGYT-01 EGFR StudyHironobu Hoshino, Shinya Katsumata, Akira Hamada, et al.
Clinical Lung Cancer|October 27, 2021
Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic CarcinomasToshio Fujino, Kenichi Suda, Kazuko Sakai, et al.
Lung Cancer (Amsterdam, Netherlands)|August 30, 2020
Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Keiko Obata, et al.
Kyobu Geka. the Japanese Journal of Thoracic Surgery|September 3, 2016
[Curative Left Pulmonary Resection Combined with Total En Bloc Spondylectomy for Lung Cancer Invading the Second and Third Thoracic Vertebral Bodies]Makoto Endoh, Hiroyuki Oizumi, Hirohisa Kato, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2021
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancerShuta Ohara, Kenichi Suda, Toshio Fujino, et al.
Cancers|December 30, 2025
Refining Surgical Standards: The Role of Robotic-Assisted Segmentectomy in Early-Stage Non-Small-Cell Lung CancerMasaya Nishino, Hideki Ujiie, Masaoki Ito, et al.
Translational Lung Cancer Research|September 29, 2021
Activity and mechanism of acquired resistance to tarloxotinib in <i>HER2</i> mutant lung cancer: an <i>in vitro</i> studyTakamasa Koga, Kenichi Suda, Masaya Nishino, et al.
Clinical Lung Cancer|May 10, 2026
A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)Noriko Mitome, Akira Hamada, Masashi Wakabayashi, et al.
Surgery Today|February 21, 2021
The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgeryToshiki Takemoto, Junichi Soh, Shuta Ohara, et al.
Kyobu Geka. the Japanese Journal of Thoracic Surgery|July 2, 2016
[Chest Wall Reconstruction Using Titanium Plates Sandwiched Between Sheets after Resection of Chest Wall Chondrosarcoma]Makoto Endoh, Hiroyuki Oizumi, Hirohisa Kato, et al.
Pageof 9